FDA Chief Wants Doctor Education on Opioid Prescribing

FDA Chief Wants Doctor Education on Opioid Prescribing

In its latest move to curb the prescription opioid abuse epidemic, the FDA wants drugmakers to provide educational programs about managing pain and responsible ways of using opioids to doctors and other healthcare professionals.

FDA Commissioner Scott Gottlieb, speaking Monday at the start of a 2-day meeting on the impact of abuse-resistant opioids, said that the training would apply to immediate-release opioids, which account for 90% of the 200 million opioid prescriptions he says are written each year. Most of the opioids that have abuse-deterrent properties — which make them difficult to inject or snort — are extended-release versions.

“The new training will be aimed at making sure providers who write prescriptions for the IR opioids are doing so for properly indicated patients, and under appropriate clinical circumstances,” he said. He added that the training would also look at non-pharmacological methods and non-opioid drugs to deal with pain.

Gottlieb also said the FDA will survey physicians to find out their views on abuse-deterrent opioids, since he is concerned many of them may mistakenly believe that these drugs are somehow less likely to lead to addiction. “Patients can still become addicted to opioid products with abuse-deterrent features,” he noted.

In an interview with NBC News, Gottlieb said that opioid prescriptions should be written for a shorter period of time. “I believe there are still too many 30-day prescriptions being written for conditions like dental procedures or minor surgery, which should require very short-term use, if they require an opioid prescription at all,” he told the network.

The FDA meeting follows last week’s announcement from Endo International that it will comply with the agency’s request to remove its extended-release, abuse-deterrent opioid, Opana ER, from the market.


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?

No votes so far! Be the first to rate this post.


Latest News

Effects of Vitamin D and Antibiotics during Pregnancy

Effects of Vitamin D and Antibiotics during Pregnancy

A new study out today on Vitamin D and pregnancy plus two more studies on how drugs and supplements given to pregnant women affect the fetus and the offspring for years to come.  Be well.   Bone Density Taking higher doses of Vitamin D during pregnancy showed a correlation with…

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

We knew it was too good to be true – free and cheap drugs aren’t worth it. Also, taking a magic pill to lose weight could give you cancer (!). One ray of sunshine: a pain therapy device using shortwave is now available over-the-counter. Have a lovely Valentine’s Day! Be…

  • Advertisement